个性化文献订阅>期刊> Expert Opinion on Therapeutic Patents
 

Therapeutic potential of A(2) and A(3) adenosine receptor: a review of novel patented ligands

  作者 Federico, S; Spalluto, G  
  选自 期刊  Expert Opinion on Therapeutic Patents;  卷期  2012年22-4;  页码  369-390  
  关联知识点  
 

[摘要]Introduction: Adenosine exerts its effects by interacting with G-protein coupled receptors (GPCR) namely A(1), A(2A), A(2B) and A(3), respectively. These are involved in several diseases, for example and most importantly, Parkinson's disease, ischemia and inflammation. There is high interest in the development of potent and selective ligands for these adenosine receptor (AR) subtypes, primarily for their therapeutic potential but also as pharmacological tools in receptor studies.Areas covered: This paper concentrates on reviewing the therapeutic potential of A(2) and A(3) ARs, which represent the most interesting subtypes of recent years. A general description of each receptor is reported with novel agonist and antagonist structures, patented in 2008 - 2011. PubMed and Free Patents Online databases were principally used to collect all the material.Expert opinion: In the past years, by modulating A(2) and A(3)ARs, several new possible therapeutic applications were discovered. For this reason, research concerning AR ligands is still of great interest. In particular, few potent and selective A(2B) agonists and antagonists are actually reported and a clear SAR (structure-activity relationship) profile lacks for this AR subtype. At the A(3)AR, allosteric modulation may prevent problems related to the high difference between rat and human orthosteric sites and simplify the preclinical studies on A(3)AR.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内